Article Information
History
- January 22, 2022.
Article Versions
- Version 1 (January 21, 2022 - 22:36).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- 1Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, 1985 Zonal Ave, Los Angeles, CA 90033, USA
- 2Certara UK Ltd, Simcyp Division, 1 Concourse Way, Level 2-Acero, Sheffield, S1 2BJ, United Kingdom
- 3Division of Pulmonary and Critical Care Medicine, Department of Medicine, Keck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA
- 4USC Anton Yelchin CF Clinic, 1510 San Pablo St, Los Angeles, CA 90033, USA
- ↵* Corresponding author: 1985 Zonal Avenue, Los Angeles, CA 90033, USA, Tel: 323-442-1402, Fax: 323-442-1395, Email: beringer{at}usc.edu
Posted January 22, 2022.
PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19
